Nvidia plans to take a minority stake in French health platform Doctolib, whose research programme uses personal data from 50 million users, chief executive Jensen Huang announced in Paris on 13 October, Le Monde reported.
Key points
- Nvidia will be a minority shareholder without a seat on Doctolib’s board, Doctolib’s chief executive said.
- Doctolib plans to put the capital towards hiring and development of its own AI models.
- Huang said Nvidia invested at least $8 billion in Europe in 2025 and has also invested in French AI companies Genesis IA and Pigment.
- Doctolib’s last reported valuation, in spring 2026, was 3,6 billion euros.
Nvidia’s Doctolib stake carries no board seat
Stanislas Niox-Château, Doctolib’s chief executive and co-founder, told AFP that Nvidia would join its shareholders without taking a seat on the board. Doctolib operates a platform for booking medical appointments. The capital will go to the French company, which plans to hire staff and speed development of its proprietary AI models.
In its last reported valuation in spring 2026, Doctolib was worth 3,6 billion euros. The investment announced by Huang is a minority position, while Niox-Château described hiring and model development as the intended uses of the money. Huang set out Nvidia’s European investment figures at the Paris press conference.
Huang said Nvidia invested at least $8 billion in Europe in 2025. He also said it had invested in Genesis IA and Pigment, two French AI companies. He said the Doctolib investment was intended to start an AI revolution in Europe.
Nvidia has also backed Mistral, Tech Funding News reported. Mistral raised a €3 billion Series D on 8 September 2026 at a valuation above €21 billion. Samsung Electronics led that round, in which Nvidia participated.
Doctolib plans its own healthcare models
Niox-Château said the Nvidia investment would let Doctolib recruit more staff and advance its proprietary AI models. Those models are intended to avoid dependence on providers such as OpenAI and Anthropic. Doctolib plans to use Nvidia chips, computing capacity and open software in the development work.
Niox-Château said the company wanted AI trained using its own models and data, with Doctolib retaining control. According to Tech Funding News, the company’s release said Doctolib would work from open models, house health data in the EU and the UK and retain exclusive authority over that data. The same release said the investment would support AI hiring and give Doctolib access to Nvidia experts for model training in Europe.
The work includes a personal health assistant for patients, Niox-Château said. Doctolib is also developing assistants for healthcare professionals that would cover administrative and clinical tasks. He said Nvidia’s investment would allow the company to move faster on those products.
Doctolib’s 50 million-user research programme
Doctolib launched a scientific research programme in August 2026 using personal data from its 50 million users. The programme is intended to improve healthcare pathways through AI. It forms another part of the company’s AI work alongside the patient and professional assistants described by Niox-Château.
Doctolib plans to make assistants for healthcare professionals a major priority in 2027–2028, Niox-Château said.
